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Abstract
Utilization of neuropharmaceuticals for central nervous system(CNS) disease is highly limited due to the blood-brain
barrier(BBB) which restricts molecules larger than 500Da from reaching the CNS. The development of a reliable method to
bypass the BBB would represent an enormous advance in neuropharmacology enabling the use of many potential disease
modifying therapies. Previous attempts such as transcranial catheter implantation have proven to be temporary and
associated with multiple complications. Here we describe a novel method of creating a semipermeable window in the BBB
using purely autologous tissues to allow for high molecular weight(HMW) drug delivery to the CNS. This approach is
inspired by recent advances in human endoscopic transnasal skull base surgical techniques and involves engrafting
semipermeable nasal mucosa within a surgical defect in the BBB. The mucosal graft thereby creates a permanent
transmucosal conduit for drugs to access the CNS. The main objective of this study was to develop a murine model of this
technique and use it to evaluate transmucosal permeability for the purpose of direct drug delivery to the brain. Using this
model we demonstrate that mucosal grafts allow for the transport of molecules up to 500 kDa directly to the brain in both a
time and molecular weight dependent fashion. Markers up to 40 kDa were found within the striatum suggesting a potential
role for this technique in the treatment of Parkinson’s disease. This proof of principle study demonstrates that mucosal
engrafting represents the first permanent and stable method of bypassing the BBB thereby providing a pathway for HMW
therapeutics directly into the CNS.
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Introduction
Neurologic disorders affect more than 20 million patients in the
US alone and account for over $400 billion in annual expenditure
for both their treatment and chronic care [1,2]. The paucity of
effective neurodegenerative therapies is directly attributable to the
presence of the blood-brain barrier(BBB) and blood-cerebrospinal
fluid barrier(BCSFB). These barriers are composed of densely
packed cells with copious intercellular tight junctions(TJ), active
efflux pumps, and a trilamellar basement membrane which
prevent the absorption of polar or high molecular weight(HMW)
molecules larger than 500Da [3]. This results in restriction of up to
98% of all potential neuropharmaceutical agents from reaching
the central nervous system(CNS) [3]. Consequently, known
charged or macromolecular therapies which may be capable of
preventing or even reversing certain neurologic diseases are
rendered clinically ineffective due to their inability to cross the
BBB.
The limitations of the BBB have catalyzed a considerable
research effort into ways to circumvent this barrier. Currently
described experimental methods such as transcranial catheter
placement [4] and the use of protein conjugates [1] may be
invasive or require extensive drug manipulation to optimize trans-
BBB transport rendering them impractical, morbid, and expensive
to scale up for widespread clinical use. Furthermore even if the
BBB could be successfully overcome, the majority of these
strategies rely on a peripheral delivery route leading to potential
systemic toxicity and pulsatile CNS delivery [2].
The evident value of a direct pathway capable of continuous
delivery of polar and macromolecular therapies has led to a large
body of work seeking to exploit the olfactory mucosa for this
purpose. Trans-olfactory CNS uptake of nerve growth fac-
tor(NGF, 27.5 kDa) has been described in rats [5] and Fisher
et al [6] suggested that absorption of even larger molecules may be
possible. The findings in rodent models have ultimately failed to
translate into clinical success largely due to the relatively
diminutive presence and distribution of the human olfactory
mucosa [7]. However, confirmation of the permeability of nasal
mucosa to very large and polar molecules suggests the potential for
a novel alternative method.
Using recently developed endoscopic techniques, surgeons are
now routinely able to remove brain tumors through the nose
without any facial incisions. These approaches require the removal
of the intervening dura mater and arachnoid membrane thereby
creating a large communication between the interior of the nose
and the brain surface. In order to prevent post-operative infection
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e61694or leakage of cerebrospinal fluid, these holes in the skull base are
then sealed using nasal mucosal grafts harvested from the nasal
septum [8](Fig. 1A). While these repairs are permanent, water
tight, and immunocompetent [9], they also function to replace
large regions of the restrictive BCSFB within the arachnoid with
relatively permeable sinonasal mucosa. The engrafted nasal
mucosa may be subsequently dosed with a variety of therapeutic
agents applied topically. Given the lack of underlying arachnoid
membrane, these mucosal grafts have the potential to bypass the
BBB and transmit HMW or polar agents directly to the brain and
subarachnoid space using purely autologous tissues.
The purpose of this study is to determine the capacity of these
septal mucosal grafts for permitting diffusion of high molecular
weight markers into the CNS. In order to analyze the impact of
size and exposure duration on marker delivery, we developed a
novel murine extracranial graft model that precisely recapitulates
the anatomy and graft morphology encountered at the anterior
skull base. Here we provide a proof of concept demonstration that
mucosal engrafting of the BBB enables the delivery of HMW
molecules to the CNS while obviating the need to implant foreign
bodies or penetrate the brain parenchyma.
Results
Outcomes of Mucosal Engrafting and Impact on
Rhodamine-dextran Marker Uptake
To directly examine the efficiency of nasal mucosa in
transporting HMW agents, we first developed and validated a
murine model to mimic the human skull base. In this model, a
mucosal graft harvested from a donor mouse septum was applied
over a right parietal craniotomy 3 mm in diameter following dural
reflection(Fig. 1B–D). A reservoir was surgically implanted over
Figure 1. Murine graft model. A) Sagittal MRI of a patient following endoscopic reconstruction of a skull base defect using a nasal mucosa
graft(dotted white line, arrow denotes the proposed transmucosal pathway for HMW agents from the nose into the CNS through the graft). B)
Illlustration of the murine graft model with the position of the graft(red circle) relative to the skull. The arrow denotes the equivalent transmucosal
pathway to that seen on the MRI(Fig. 1A) utilized in our study. C and D) Cross sectional illustration of the skull base layers prior to and following
craniotomy with dural removal and mucosal graft inset, respectively. Note that the dural layer(dura and arachnoid) contains the blood-cerebrospinal
fluid barrier which restricts the transport of HMW molecules. E) Hematoxylin and eosin(H&E) section of the intact murine parietal bone with typical
appearance of the inner and outer cortical tables with their associated diploic space(D) prior to engrafting(bar=200 mm). F) H&E section of the
mucosal graft implant in direct continuity with underlying brain parenchyma. Note the intact epithelial layer(E) consisting of pseudostratified
columnar epithelium.
doi:10.1371/journal.pone.0061694.g001
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graft with different fluorescent rhodamine-dextran markers
ranging from 20–500 kDa. The mucosal implant procedure was
well tolerated and no evidence of subcutaneous infection,
mucocele, or distress related to the surgical site was observed
during the postoperative period. Hematoxylin and eosin staining
demonstrated intact grafts with complete coverage of the bony
craniotomy(Fig. 1E,F). Evans blue(EB) staining was used to
confirm the integrity of the epithelial tight junctions within the
graft following exposure to the rhodamine-dextran solution. The
EB dye was restricted to the apical surface in all grafts indicating
viable and intact epithelium(Fig. 2A). The validity of the technique
was verified by calculating the total area of rhodamine diffusion in
the control conditions directly adjacent to the graft(bregma
21.06 mm). The positive control consisted of direct exposure of
the brain to the rhodamine-dextran solution with no intervening
dura or mucosa. This resulted in a large area of ipsilateral
500 kDa rhodamine-dextran diffusion(1206.03+/2509.44 mm
2,
mean+/2S.D., n=3). The negative control condition in which
the dura was kept intact demonstrated negligible diffusion(1.36+/
21.3 mm
2, n=3)(Fig. 2A). Direct intranasal dosing has also been
reported to allow for high molecular weight drug delivery to the
brain in rodents [5] however this method is inefficient and likely
not translatable to humans. In order to directly compare delivery
via the mucosal graft with intranasal dosing we applied an
equivalent volume of the 20 kDa rhodamine-dextran solution
directly into the nostril. The intranasal delivery condition
demonstrated minimal delivery which was similar to that of the
negative control(1.76+/22.17 mm
2, n=3)(Fig. 2A).
Transmucosal Rhodamine-dextran Diffusion by Molecular
Weight and Time
We next examined the impact of molecular weight and duration
of exposure on transmucosal rhodamine-dextran diffusion. Poly-
mers of molecular weights 20, 40 and 500 kDa were tested. At
designated time points, mice were euthanized and coronal brain
slices were imaged in order to calculate the area and intensity of
rhodamine within a cross section incorporating the leading edge of
the mucosal graft. As shown in Fig. 2A the degree of marker
diffusion at 24 hours was directly related to polymer molecular
weight. The calculated area of polymer diffusion after 72 hours of
administration shows a trend of an increase in area with
decreasing molecular weight (Fig. 2B). We next focused on the
distribution of the more therapeutically relevant lower molecular
weight markers. The 20 kDa marker demonstrated a trend
towards greater percent distribution and weighted luminosity than
the 40 kDa dextran at all time points. This trend reached statistical
significance for the percent distribution at 72 h(p,0.05)(Fig. 3).
The percent of total cross sectional area stained by rhodamine
successively increased with longer exposure(Fig. 3A,B). The 72 h
time point demonstrated the greatest percent distribution for both
the 20 and 40 kDa dextran markers(14.89+/23.86%, 9.08+/
25.16%, mean+/2S.D.; n=3, respectively)(Fig. 3C). In order to
further compare the relative concentrations of rhodamine delivery
over time, a weighted luminosity average was calculated over the
entire cross section. For both the 20 and 40 kDa dextran
molecules, the weighted luminosity successively increased over
time with the 72 h time point demonstrating the greatest
intensity(106.46+/258.39, 48.65+/228.46; n=3,
respectively)(Fig. 3D).
Striatal Delivery of Transmucosal Rhodamine-dextran
In order to ascertain whether the mucosal graft method could
be utilized to deliver macromolecular therapies to the striatum for
treating Parkinson’s disease(PD), striatal delivery was examined.
The difference between the average luminosity of the right(-
ipsilateral to the mucosal graft) and left striatum(bregma 1.18 mm)
was calculated over 12 to 72 hours of continuous exposure to the
20, 40, and 500 kDa rhodamine-dextran marker solutions.
Ipsilateral striatal staining was seen among both the 20 and
40 kDa conditions however staining was negligible for the highest
molecular weight 500 kDa polymer. The differential striatal
luminosity at 72 hours for the 20 kDa marker was significantly
greater than that at 12 hours(5.62+/23.58 vs. 1.94+/23.99,
mean+/2S.D., n=3, p,0.05)(Fig. 4). As expected, contralateral
staining was not detected for any of the molecular weights or
exposure durations. These results demonstrate the feasibility of
delivering HMW therapies such as growth factors to the striatum
as these proteins are of comparable molecular weights to the
polymers tested in this study. Among all conditions no significant
delivery to the substantia nigra was evident.
Discussion
The BBB represents one of the major obstacles to the
development and implementation of therapies for the treatment
of neurodegenerative disease. Neurotrophic factors with known
disease modifying capabilities in Parkinson’s Disease have failed to
be adopted into routine clinical use due to, in part, their inability
to cross the BBB. Glial derived neurotrophic factor(GDNF)
represents one such molecule which can promote mesencephalic
dopaminergic neuronal survival and modulate neuronal function
[10]. Given the size of the dimeric GDNF peptide(25–30 kDa),
therapeutic efficacy studies have required the implantation of
intracerebroventricular or intraputamenal catheters in order to
provide access to the CNS. One clinical trial examining direct
intraputamenal delivery reported that all patients developed
vasogenic edema at the catheter tip and 40% required additional
catheter manipulation or explantation [11]. These findings suggest
that while direct, continuous delivery of neurotrophic or other
experimental HMW molecules to the CSF have tremendous
potential, there remains a need for a safer and more permanent
alternative to the transcranial implantation of indwelling foreign
bodies.
Intranasal drug delivery has been investigated as an alternative
potential method to deliver therapeutic agents to the CNS thereby
avoiding trauma to the brain parenchyma or implantation of
foreign bodies. While the intranasal route for systemic adminis-
tration is currently utilized for PD therapies such as apomorphine
[12], its utility in direct CNS delivery is controversial. The
anatomic basis for this theory arises from the fact that the
subarachnoid space extends into the nasal cavity along the
olfactory neurons allowing for the rapid uptake of large molecules
into the CSF compartment [13]. While this delivery route has
been successfully demonstrated in animal models [14], its clinical
utility is less clear. The relative paucity of human olfactory mucosa
coupled with its location in a region with little access for topical
agents [15] suggests that these rodent studies may vastly overstate
the clinical potential of transnasal CNS delivery through an intact
skull base. In a critical analysis of 100 papers examining this
pathway only 2 approached satisfactory evidence for utility of the
transnasal route [16]. Our findings demonstrating a relative lack of
rhodamine uptake following intranasal instillation supports this
contention.
The described mucosal grafting method represents an adapta-
tion of a surgical technique which is currently in widespread use in
the field of endoscopic skull base surgery and is, in fact, considered
the gold standard in reconstruction of skull base defects [9,17]. In
Mucosal Grafting of the Blood-Brain Barrier
PLOS ONE | www.plosone.org 3 April 2013 | Volume 8 | Issue 4 | e61694Figure 2. Transmucosal marker diffusion by molecular weight. A) Fluorescent microscopic images demonstrating transmucosal rhodamine-
dextran delivery(bar=1 mm, bregma 21.06 mm, * denotes the position of the reservoir containing the rhodamine-dextran solution in all of the
topical delivery conditions). Negative(neg) and positive(pos) control images represent delivery through intact dura or direct parenchymal delivery
with no intervening dura or mucosa, respectively. Note the lack of apparent fluorescence in the nasal group in which the 20 kDa rhodamine-dextran
solution is delivered directly into the nares. A molecular weight dependent successive reduction in area stained is seen between 20, 40, and 500 kDa
rhodamine-dextran. The bottom row represents matched brightfield images demonstrating the mucosal graft stained with Evans blue used to
confirm mucosal graft integrity following dosing. B) Graph depicting total area of fluorescent pixels at bregma 21.06 mm following 72 hours of
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delivery, an appropriate animal model had to be developed and
validated. While the described murine extracranial model does not
replicate the intranasal milieu, it precisely recapitulates the skull
base morphology following surgical mucosal graft reconstruction.
The discreet lack of rhodamine-dextran uptake in the negative
control condition confirmed that the BCSFB was present and
intact in the murine arachnoid. Additionally it was critical to
validate the integrity of each mucosal graft following rhodamine-
dextran exposure to ensure that the observed absorption could not
be attributed to a disruption of the epithelium secondary to poor
healing or surgical trauma. The described Evans blue testing
confirmed that all of the observed rhodamine-dextran absorption
resulted from transport through an intact mucosal graft.
Our data demonstrate that while the mucosal grafts were
permeable to all of the dextran molecules tested, there was a clear
and significant decrement in transport as molecular weight
increased. This supports that fact that the mucosal epithelium,
while significantly more permeable than the BBB, also exerts some
measure of size selectivity on the molecules it is exposed to. This
was overcome, in part, by extending the exposure duration. This
could be achieved clinically using a variety of drug eluting
polymers. Given the potential for use of this technique for
neurotrophic factor delivery in PD, this study also sought to
examine the relative uptake in the striatum, a potential end organ
target for GDNF. Our data show that while the 500 kDa could be
detected, significant ipsilateral delivery was seen only up to
40 kDa. The lack of contralateral diffusion is consistent with the
unilateral bias of the mucosal graft coupled with the known
limitations of drug diffusion through the extracellular spaces within
the brain [18]. In clinical use however, the mucosal graft is
positioned in the midline proximal to the mesencephalon and
adjacent to the prepontine and interpeduncular cisterns thereby
providing bilateral access for drug delivery.
One limitation of this study is that it does not address whether
the findings in our animal model would be applicable in a clinical
setting due to regional differences in convection throughout the
brain. When directly comparing the murine model to the human
skull base however, the reported findings may actually underes-
timate the potential for drug delivery for two important reasons.
The first is that in the human, the relative mucosal graft area to
brain volume ratio would be much higher given that grafts up to
20cm
2 are achievable. Additionally in the clinical scenario,
diffusion to more distal aspects of the brain would be possible
via CSF circulation, a finding not seen in the murine model due to
occlusion of the smaller subarachnoid space following the
craniotomy.
rhodamine-dextran delivery. The total area of delivery under all molecular weight conditions is significantly greater than that seen following direct
intranasal instillation of a 20 kDa rhodamine-dextran solution(p,0.05).
doi:10.1371/journal.pone.0061694.g002
Figure 3. Area and intensity of marker diffusion over time. A)Fluorescent microscopic images demonstrating an increase in area and intensity
of transmucosal rhodamine-dextran delivery over time(bar=1 mm, bregma 21.06 mm, 40 kDa rhodamine-dextran). B) 3-D map of Fig. 3A
quantifying increase in relative pixel luminosity intensity across each cross section over time(bregma 21.06 mm, 40 kDa rhodamine-dextran). C)
Percent of the total cross sectional area containing detectable rhodamine fluorescence at bregma 21.06 mm. The overall trend describes an
increasing percent area of staining as time increases and molecular weight decreases. Among the 40 kDa conditions, the percent area of rhodamine
staining at 72 h is significantly greater than at 12 or 48 h. Among the 20 kDa conditions the percent area of rhodamine staining at 72 h is significantly
greater than at 12 h. At 72 h, the percent area subtended by the 20 kDa condition is significantly greater than that of the 40 kDa condition. D)
Weighted luminosity of rhodamine staining at bregma 21.06 mm. The overall trend describes an increasing weighted luminosity as time increases
and molecular weight decreases. Among the 40 kDa conditions, the weighted luminosity at 72 h is significantly greater than at 12 or 48 h. Among
the 20 kDa conditions, the weighted luminosity at 72 h is significantly greater than at 12 h.
doi:10.1371/journal.pone.0061694.g003
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to bypass the BBB providing a permanent route for direct CNS
drug delivery using only autologous tissues. The mucosal graft
represents a non-specific semipermeable membrane that could be
compatible with both established and experimental HMW
therapeutics including neurotrophic factors, fusion proteins [10],
nanoparticles [19], and viruses [20]. This proof of concept study
also suggests that the mucosal graft enables the delivery of
molecules up to 40 kDa(the size of GDNF) to the striatum while
obviating the need to implant foreign bodies or penetrate the brain
parenchyma. Given the fact that this surgical technique is
currently in clinical use, additional efforts will be directed at
therapeutic efficacy studies which will form the basis for future
clinical trials.
Materials and Methods
Ethics
All procedures involving animals are approved by the Boston
University Institutional Animal Care and Use Committee.
Experimental Design
Following engrafting of the heterotopic mucosal graft(described
under surgical methods) in 20–25 g C57BL/6 mice, the mucosa is
exposed to a 60 mL rhodamine-dextran solution. The adminis-
tered solutions are standardized by fluorophore content. Rhoda-
mine conjugated dextran solutions (Sigma, molecular weights of
20, 40, or 500 kDa) were dissolved in saline and titrated until an
absorbance of 0.67 at 520 nm is obtained. Absorbance spectra are
obtained using 2 mL of solution in a NanoDrop 2000 spectro-
photometer(Thermo Scientific). Positive control groups are mice in
which the rhodamine-dextran solution is applied directly to the
parenchymal surface following craniotomy and reflection of the
underlying dura and arachnoid membrane. Negative control
groups are mice in which a craniotomy is performed leaving the
underlying dura and arachnoid intact. The intranasal group
consists of direct instillation of 60 mL of the 20 kDa rhodamine-
dextran solution in 10 mL increments while the mouse was
anesthetized using isoflurane.
Surgical Methods
In order to perform the heterotopic mucosal engrafting
procedure, a donor mouse is used to harvest the nasal septum en
bloc according to previously described methods [21]. The septal
mucoperichondrial flaps are preserved in normal saline for no
more than 2 hours prior to engrafting. The experimental mouse is
anesthetized using isoflurane and placed in a stereotaxic frame
below an operating microscope. Following standard prepping and
clipping of the scalp, a linear sagittal incision is made from the
level of the mid orbit to the occiput. Flaps are elevated bilaterally
in a subgaleal plane exposing the pericranium. The pericranium is
then cleared from the intended craniotomy site centered at
21.5 mm anterior-posterior, and,2 mm medial-lateral to breg-
ma. Using a drill, a craniotomy 3 mm in diameter is outlined. The
bone is then carefully reflected leaving the underlying dura intact.
In the experimental mice, the dura and arachnoid are then
reflected leaving the underlying pia mater undisrupted. This is
accomplished by applying Vetbond(3 M) to the dural surface.
Once dried, the membrane can be manually removed without
damaging the brain surface. The previously harvested mucosal
graft is then inset taking care to place the mucoperichondrial layer
against the exposed pia mater. The skin flaps are then closed and
the flap is left to engraft for 7 days.
Figure 4. Transmucosal marker delivery to striatum over time.
A) Fluorescent microscopic images demonstrating transmucosal
rhodamine-dextran delivery to the striatum(bregma 1.18 mm,
bar=0.5 mm, 72 h). Diffusion into the right striatum(ipsilateral to
mucosal graft) occurs in a molecular weight dependent fashion while
contralateral diffusion to the left striatum is negligible. B) The
differential luminosity of the right(ipsilateral) striatum relative to the
contralateral striatum following rhodamine-dextran exposure. While
detectable striatal diffusion of the 20 and 40 kDa rhodamine-dextran
conditions is seen, the 500 kDa rhodamine-dextran solution is
associated with negligible striatal delivery. The differential luminosity
of the striatum at 72 h following 20 kDa rhodamine-dextran delivery is
significantly greater than at 12 h.
doi:10.1371/journal.pone.0061694.g004
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leave the underlying mucosal graft undisturbed. The graft is then
inspected using a dissecting microscope to ensure there is no
evidence of defects, infection, necrosis, or exposed bony edges. A
100 mL polypropylene reservoir is then inset over the graft and
secured to the cranium using polycyanoacrylate followed by dental
cement(Stoelting). The reservoir is checked for leaks and the
desired rhodamine-dextran solution is then applied to the reservoir
ensuring the solution comes into direct contact with the mucosal
surface.
Histologic Preparation and Imaging
Following rhodamine-dextran dosing according to the assigned
group, the solution is removed and replaced with Evans blue(EB,
961Da, Sigma) for 1 hour. Defects or disruptions in the graft
epithelium will allow for EB diffusion into the underlying brain
parenchyma over this short exposure time. Apical restriction of the
dye is therefore used to confirm graft integrity during the
preceding rhodamine-dextran dosing interval. The mice are
euthanized using pentobarbital until unresponsive to a foot
withdrawal reflex. The brain is then harvested en bloc and snap
frozen in a 2-methylbutane dry ice bath. The brain is then
mounted in OCT(Sigma) and sectioned at a thickness of 50 mm
using a crytostat(Leica). In order to prevent rhodamine diffusion
into the mounting media, sections are immediately imaged using
an Olympus IX81 microscope equipped with Metamorph
software. Rhodamine containing samples are imaged at 46using
a red filter with a 1000 ms exposure time. Evan’s Blue containing
samples are imaged at 46 in phase-contrast mode with a 15 ms
exposure time. Images are merged and exported for luminosity
analysis in tagged image file format(TIFF).
Image Analysis
Rhodamine luminosity is quantified according to methods
adapted from Kirkeby et al [22]. All TIFF files are imported into a
graphics editing program(Adobe Photoshop) for analysis which
was confirmed using Image J. The brightness across all images is
normalized using a non-tissue bearing region of the slide. The
software is used to automatically select pixels exceeding the
background luminosity tolerance threshold in each image. The
total number of pixels and mean luminosity of all selected pixels
are recorded for each image. A weighted luminosity was calculated
by multiplying the average luminosity over all pixels by the total
number of fluorescent pixels. In order to measure striatal
luminosity, a brightfield image is superimposed over the fluores-
cent image and the striatum was selected by hand. The brightfield
image is then removed and the luminosity of the selected region is
recorded. The differential luminosity is calculated by subtracting
the luminosity of the ipsilateral from the contralateral striatum(re-
lative to the graft).
Statistics
The significance of differences across the experimental and
control conditions is determined using a 2 tailed Student’s t-
test(SigmaStat v3.1, Systat Software Inc, San Jose, CA). Differ-
ences are considered statistically significant at p,0.05.
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